<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248170</url>
  </required_header>
  <id_info>
    <org_study_id>CFEM345D2411</org_study_id>
    <secondary_id>2005-004263-35</secondary_id>
    <secondary_id>EUDRACT number 2005-004263-35</secondary_id>
    <nct_id>NCT00248170</nct_id>
  </id_info>
  <brief_title>Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer</brief_title>
  <acronym>FACE</acronym>
  <official_title>Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females
      who recently underwent primary surgery for breast cancer. Patients will be randomized to
      letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up
      will occur for 5 years after the completion of enrollment for survival and disease status
      updates.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>84 months</time_frame>
    <description>Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>84 months</time_frame>
    <description>Overall survival was defined as the time from the date of randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Development of Distant Metastases</measure>
    <time_frame>84 months</time_frame>
    <description>Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Development of Contra Lateral Breast Cancer</measure>
    <time_frame>84 months</time_frame>
    <description>Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Disease-free Survival</measure>
    <time_frame>84 months</time_frame>
    <description>Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Lipid Profiles</measure>
    <time_frame>baseline, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Clinical Fracture Events</measure>
    <time_frame>84 months</time_frame>
    <description>The incidence of clinical fractures was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Cardiovascular Events</measure>
    <time_frame>84 months</time_frame>
    <description>The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4172</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg by mouth (p.o.) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg p.o. once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5 mg tablets</description>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg tablets</description>
    <arm_group_label>Anastrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent primary surgery for breast cancer

          -  Early stage breast cancer

          -  Postmenopausal

          -  Hormone receptor positive

          -  Positive lymph node involvement

        Exclusion Criteria:

          -  Metastatic disease

          -  Presence of contralateral breast cancer including DCIS

          -  Progression

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>33 Years</minimum_age>
    <maximum_age>96 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Hematology and Oncology Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Arizona Hematology/Oncology Associates, P.C.</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology &amp; Hematology Associates, PC</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Meyers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida PA</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Oncology Associates</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita Community Clinical Oncology Program</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer &amp; Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer &amp; Breast Institute</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. NYOH Latham</name>
      <address>
        <city>Troy</city>
        <state>New York</state>
        <zip>12180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Hematology Oncology Associates</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Oncology Hematology Care, Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Associates of Oregon, PC</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401-8122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates of Wyorning Valley, PC</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology and Hematology Assoicates, PC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Oncology Research and Treatment, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center ( Medical City Dallas Hospital)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Presbyterian Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Texas Oncology PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center Denton</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Cancer Treatment Ctr-East</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Tumor and Blood Clinic</name>
      <address>
        <city>Fredericksburg</city>
        <state>Texas</state>
        <zip>78624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cancer Center- McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allison Cancer Center</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701-5946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center- Sherman</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090-0504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waco Cancer and Research Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancover</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Redcliff</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Franston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Auckland</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dunedin</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Friesach</city>
        <zip>9360</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Güssing</city>
        <zip>7540</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herning</city>
        <zip>DK-7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hillerød</city>
        <zip>DK-3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Næstved</city>
        <zip>DK-4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers cedex 9</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>F-69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montbeliard</city>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>F-34094</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06050</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Périgueux Cédex</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bremen</city>
        <zip>28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle/'Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lüneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 24</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Letterkenny</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montevarchi</city>
        <state>AR</state>
        <zip>52025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Biella</city>
        <state>BI</state>
        <zip>13051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antella - Bagno a Ripoli</city>
        <state>FI</state>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Forli</city>
        <state>FO</state>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>TV</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fermo</city>
        <zip>63122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>01812</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Enschede</city>
        <zip>7511 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skien</city>
        <zip>NO-3710</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>A Coruna</city>
        <state>Galicia</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schaffhausen</city>
        <zip>8208</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS16 1JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelmsford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colchester</city>
        <zip>CO3 3NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merseyside</city>
        <zip>L63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rhyl</city>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffiled</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY38XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2005</study_first_posted>
  <results_first_submitted>September 8, 2015</results_first_submitted>
  <results_first_submitted_qc>September 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 9, 2015</results_first_posted>
  <last_update_submitted>March 20, 2016</last_update_submitted>
  <last_update_submitted_qc>March 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>letrozole</keyword>
  <keyword>anastrozole</keyword>
  <keyword>adjuvant</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>FACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants, who had recently undergone surgery, were randomly assigned in 1:1 ratio to letrozole or anastrozole. Participants received daily treatment until disease recurrence/relapse or for a maximum of 5 years. Participants underwent post-treatment long term follow-up for disease-free survival and overall survival.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Letrozole</title>
          <description>2.5 mg by mouth (p.o.) once daily</description>
        </group>
        <group group_id="P2">
          <title>Anastrozole</title>
          <description>1 mg p.o. once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2078"/>
                <participants group_id="P2" count="2094"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="2061"/>
                <participants group_id="P2" count="2075"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="2049"/>
                <participants group_id="P2" count="2062"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1317"/>
                <participants group_id="P2" count="1286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="761"/>
                <participants group_id="P2" count="808"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="216"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="296"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure(s) result</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Letrozole</title>
          <description>2.5 mg by mouth (p.o.) once daily</description>
        </group>
        <group group_id="B2">
          <title>Anastrozole</title>
          <description>1 mg p.o. once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2061"/>
            <count group_id="B2" value="2075"/>
            <count group_id="B3" value="4136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="8.48"/>
                    <measurement group_id="B2" value="63.1" spread="8.45"/>
                    <measurement group_id="B3" value="63.2" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2061"/>
                    <measurement group_id="B2" value="2075"/>
                    <measurement group_id="B3" value="4136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival</title>
        <description>Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.</description>
        <time_frame>84 months</time_frame>
        <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival</title>
          <description>Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.</description>
          <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2061"/>
                <count group_id="O2" value="2075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="84.14">The median was not reached and therefore, could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached and therefore, could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3150</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from the date of randomization to the date of death from any cause.</description>
        <time_frame>84 months</time_frame>
        <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from the date of randomization to the date of death from any cause.</description>
          <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2061"/>
                <count group_id="O2" value="2075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached and therefore, the median could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached and therefore, the median could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Development of Distant Metastases</title>
        <description>Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.</description>
        <time_frame>84 months</time_frame>
        <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Development of Distant Metastases</title>
          <description>Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.</description>
          <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2061"/>
                <count group_id="O2" value="2075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="84.14">The median was not reached and therefore, the median could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached and therefore, the median could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Development of Contra Lateral Breast Cancer</title>
        <description>Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.</description>
        <time_frame>84 months</time_frame>
        <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Development of Contra Lateral Breast Cancer</title>
          <description>Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.</description>
          <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2061"/>
                <count group_id="O2" value="2075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not reached and therefore, the median could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached and therefore, the median could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Disease-free Survival</title>
        <description>Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.</description>
        <time_frame>84 months</time_frame>
        <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Disease-free Survival</title>
          <description>Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.</description>
          <population>Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2061"/>
                <count group_id="O2" value="2075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="84.14">The median was not reached and therefore, the median could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA">The median was not reached and therefore, the median could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Lipid Profiles</title>
        <description>Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.</description>
        <time_frame>baseline, 6, 12, 24, 36, 48 and 60 months</time_frame>
        <population>Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Lipid Profiles</title>
          <description>Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.</description>
          <population>Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2049"/>
                <count group_id="O2" value="2062"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.643" lower_limit="5.584" upper_limit="5.701"/>
                    <measurement group_id="O2" value="5.553" lower_limit="5.495" upper_limit="5.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.569" lower_limit="5.510" upper_limit="5.629"/>
                    <measurement group_id="O2" value="5.511" lower_limit="5.452" upper_limit="5.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.508" lower_limit="5.445" upper_limit="5.572"/>
                    <measurement group_id="O2" value="5.436" lower_limit="5.373" upper_limit="5.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.429" lower_limit="5.359" upper_limit="5.500"/>
                    <measurement group_id="O2" value="5.427" lower_limit="5.357" upper_limit="5.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.395" lower_limit="5.323" upper_limit="5.468"/>
                    <measurement group_id="O2" value="5.366" lower_limit="5.293" upper_limit="5.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.375" lower_limit="5.300" upper_limit="5.451"/>
                    <measurement group_id="O2" value="5.368" lower_limit="5.292" upper_limit="5.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Clinical Fracture Events</title>
        <description>The incidence of clinical fractures was analyzed.</description>
        <time_frame>84 months</time_frame>
        <population>Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Clinical Fracture Events</title>
          <description>The incidence of clinical fractures was analyzed.</description>
          <population>Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2049"/>
                <count group_id="O2" value="2062"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Cardiovascular Events</title>
        <description>The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.</description>
        <time_frame>84 months</time_frame>
        <population>Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>2.5 mg by mouth (p.o.) once daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>1 mg p.o. once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Cardiovascular Events</title>
          <description>The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.</description>
          <population>Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2049"/>
                <count group_id="O2" value="2062"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ischemic heart disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebrovascular accidents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thromboembolic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Letrozole</title>
          <description>Letrozole</description>
        </group>
        <group group_id="E2">
          <title>Anastrozole</title>
          <description>Anastrozole</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="486" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="520" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bundle branch block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastrocardiac syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Syndactyly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Anal sphincter atony</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spigelian hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Device damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Disease recurrence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fat necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Implant site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Injection site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Patient-device incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Escherichia coli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Post procedural hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Radiation pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tracheal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Aspiration pleural cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Biopsy breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Biopsy lymph gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Carbohydrate antigen 15-3 increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mammogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mediastinal biopsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Loose body in joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Benign laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Benign lymph node neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Fibromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lip neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Neurilemmoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pleomorphic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Retro-orbital neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Signet-ring cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Superficial spreading melanoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Waldenstrom's macroglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cerebral amyloid angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Horner's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal epidural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tardive dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Somatisation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urethral caruncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Anisomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Nipple exudate bloody</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Uterine fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypertrophic scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Keloid scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Urticaria chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast lump removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast prosthesis implantation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast prosthesis removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Breast reconstruction</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Central venous catheter removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Mechanical ventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Meniscus removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Modified radical mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Removal of internal fixation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Scar excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Wound treatment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Capillary fragility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Thromboangiitis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1747" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="1762" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="345" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="341" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="983" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="983" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="666" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="666" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="2049"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

